GB201311385D0 - Method - Google Patents

Method

Info

Publication number
GB201311385D0
GB201311385D0 GBGB1311385.7A GB201311385A GB201311385D0 GB 201311385 D0 GB201311385 D0 GB 201311385D0 GB 201311385 A GB201311385 A GB 201311385A GB 201311385 D0 GB201311385 D0 GB 201311385D0
Authority
GB
United Kingdom
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1311385.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AFG Technologies SARL
Original Assignee
AFG Technologies SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AFG Technologies SARL filed Critical AFG Technologies SARL
Priority to GBGB1311385.7A priority Critical patent/GB201311385D0/en
Publication of GB201311385D0 publication Critical patent/GB201311385D0/en
Priority to PCT/EP2014/063629 priority patent/WO2014207170A1/en
Priority to GB1411429.2A priority patent/GB2519830A/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
GBGB1311385.7A 2013-06-26 2013-06-26 Method Ceased GB201311385D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB1311385.7A GB201311385D0 (en) 2013-06-26 2013-06-26 Method
PCT/EP2014/063629 WO2014207170A1 (en) 2013-06-26 2014-06-26 Methods for monitoring treatment response and relapse in ovarian cancer
GB1411429.2A GB2519830A (en) 2013-06-26 2014-06-26 Methods for monitoring treatment response and relapse in ovarian cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1311385.7A GB201311385D0 (en) 2013-06-26 2013-06-26 Method

Publications (1)

Publication Number Publication Date
GB201311385D0 true GB201311385D0 (en) 2013-08-14

Family

ID=48999008

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB1311385.7A Ceased GB201311385D0 (en) 2013-06-26 2013-06-26 Method
GB1411429.2A Withdrawn GB2519830A (en) 2013-06-26 2014-06-26 Methods for monitoring treatment response and relapse in ovarian cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB1411429.2A Withdrawn GB2519830A (en) 2013-06-26 2014-06-26 Methods for monitoring treatment response and relapse in ovarian cancer

Country Status (2)

Country Link
GB (2) GB201311385D0 (en)
WO (1) WO2014207170A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201311385D0 (en) * 2013-06-26 2013-08-14 Afg Technologies S R L Method
RU2637399C1 (en) * 2017-02-02 2017-12-04 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр" Российской академии наук ("Томский НИМЦ") Method for prediction of probability of possible execution of optimum cytoreductive operation in patients with disseminated forms of ovarian cancer
RU2658047C1 (en) * 2017-05-11 2018-06-19 Государственное автономное учреждение здравоохранения "Республиканский клинический онкологический диспансер Министерства здравоохранения Республики Татарстан" Method of estimation of risk of recurrency of ovarian cancer
RU2671409C2 (en) * 2017-12-05 2018-10-31 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Method for prediction of cytoreductive surgery volume in patients with advanced ovarian cancer after completion of third course of neoadjuvant chemotherapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2291059B (en) 1993-03-19 1997-09-24 North Sydney Area Health Serv Papp-a,its immunodetection and uses
US7462458B2 (en) 2002-05-15 2008-12-09 Mayo Foundation For Medical Education And Research Methods of detecting ovarian neoplasia
GB201311385D0 (en) * 2013-06-26 2013-08-14 Afg Technologies S R L Method

Also Published As

Publication number Publication date
GB2519830A (en) 2015-05-06
GB201411429D0 (en) 2014-08-13
WO2014207170A1 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
GB201314695D0 (en) Method
GB201318465D0 (en) Method
GB201320351D0 (en) Method
GB201309057D0 (en) Method
GB201316744D0 (en) Method
GB201309928D0 (en) Method
GB201301857D0 (en) Method
GB201316849D0 (en) Method
GB201313249D0 (en) Method
GB201309654D0 (en) Method
GB201301233D0 (en) Method
GB201300409D0 (en) Method
GB201311385D0 (en) Method
GB201305714D0 (en) Method
GB201301094D0 (en) Method
GB201314054D0 (en) Method
GB201312609D0 (en) Method
GB201311389D0 (en) Method
GB201322768D0 (en) Method
GB201320660D0 (en) Method
GB201319361D0 (en) Method
GB201318830D0 (en) Method
GB201318490D0 (en) Method
GB201317970D0 (en) Method
GB201317826D0 (en) Method

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)